Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Saposin C (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASIST
  • Sponsors Bexion Pharmaceuticals

    • Most Recent Events

    • 30 Aug 2024 Last checked against ClinicalTrials.gov record.
    • 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
    • 16 Jan 2024 According to a Bexion Pharmaceuticals media release, trials in progress poster presentation from this trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top